Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the produc... Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies. Mehr anzeigen
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate...
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical...
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the...
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will...
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.455 | -7.44680851064 | 6.11 | 6.1499 | 5.19 | 604124 | 5.42874087 | CS |
| 4 | -0.955 | -14.447806354 | 6.61 | 7.43 | 5.19 | 594615 | 6.49794673 | CS |
| 12 | -0.935 | -14.1881638847 | 6.59 | 8.275 | 5.19 | 585811 | 6.53504987 | CS |
| 26 | -2.785 | -32.9976303318 | 8.44 | 9.55 | 5.19 | 479225 | 7.14162478 | CS |
| 52 | -1.155 | -16.9603524229 | 6.81 | 11.72 | 5.19 | 582331 | 8.10272641 | CS |
| 156 | 2.435 | 75.6211180124 | 3.22 | 14.3398 | 2.54 | 459781 | 7.81461677 | CS |
| 260 | -8.685 | -60.5648535565 | 14.34 | 15.26 | 2.46 | 693789 | 6.47145497 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
